New hope for rare immune disorder patients who failed standard therapy
NCT ID NCT03933904
Summary
This study is testing a drug called sirolimus for adults with a rare immune system disorder called idiopathic multicentric Castleman disease (iMCD) who have not gotten better with standard treatments. Participants will take sirolimus daily for a year to see if it reduces symptoms like fatigue and fever and shrinks swollen lymph nodes. The goal is to see if this drug can help control the disease in patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTLEMAN DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.